680 related articles for article (PubMed ID: 29253402)
1. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
2. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
5. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
6. Cervical cancer prevention in Australia: Planning for the future.
Saville AM
Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
[TBL] [Abstract][Full Text] [Related]
7. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
[TBL] [Abstract][Full Text] [Related]
8. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
9. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
10. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
11. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
13. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program.
Machalek DA; Roberts JM; Garland SM; Thurloe J; Richards A; Chambers I; Sivertsen T; Farnsworth A
Med J Aust; 2019 Aug; 211(3):113-119. PubMed ID: 31168828
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand.
Lew JB; Simms K; Smith M; Lewis H; Neal H; Canfell K
PLoS One; 2016; 11(5):e0151619. PubMed ID: 27187495
[TBL] [Abstract][Full Text] [Related]
15. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
16. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
[TBL] [Abstract][Full Text] [Related]
17. Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.
Naber SK; Matthijsse SM; Rozemeijer K; Penning C; de Kok IM; van Ballegooijen M
PLoS One; 2016; 11(1):e0145548. PubMed ID: 26824771
[TBL] [Abstract][Full Text] [Related]
18. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
20. Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
Pedersen K; Portnoy A; Sy S; Hansen BT; Tropé A; Kim JJ; Burger EA
Int J Cancer; 2022 Feb; 150(3):491-501. PubMed ID: 34664271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
